What is the primary purpose of this 8-K filing for HCA Holdings?

The primary purpose of this 8-K filing is to disclose material information regarding compensation arrangements for HCA's executive officers and a director. Specifically, it announces the award of stock appreciation rights (SARs) to key executives and restricted stock units to a newly appointed director.

How are the stock appreciation rights structured for HCA's executives?

The SARs have a base price of $28.97 per share. They are split equally between time-based awards that vest over four years and EBITDA performance-based awards that vest annually from 2012 to 2015, contingent on meeting specific EBITDA targets determined by the Compensation Committee. The SARs are settled in company common stock.

What is the significance of the SARs being performance-based and tied to EBITDA?

Tying a portion of the SARs to EBITDA performance aligns executive compensation directly with the company's operational profitability. This incentivizes management to achieve specific earnings targets, which is a key metric for assessing a healthcare company's financial health and operational efficiency. It also signals to investors the company's focus on achieving these performance levels.

When do the stock appreciation rights and restricted stock units become fully vested?

The time-based portion of the SARs vests over four years, with 25% vesting on each of the first four anniversaries of the grant date (February 8, 2012). The performance-based portion of the SARs vests annually from fiscal year 2012 through 2015, subject to EBITDA performance targets. The restricted stock units for Dr. Riley would vest according to the terms outlined in the award agreements, which typically involve time-based vesting as well.

HCA 8-K: Leadership Changes

Summary

HCA Holdings, Inc. (HCA) filed an 8-K on February 14, 2012, primarily to report on executive compensation arrangements. The most significant information for investors concerns the award of stock appreciation rights (SARs) to key named executive officers, including the CEO Richard M. Bracken and CFO R. Milton Johnson. These SARs are designed to incentivize performance and retention, with a substantial portion tied to EBITDA performance targets over several fiscal years. Additionally, the filing details a restricted stock unit grant to a newly elected director, Dr. Wayne J. Riley. These compensation adjustments signal ongoing efforts by HCA to align executive and director interests with shareholder value, particularly in anticipation of future company performance and potential market movements. Investors should note the base price of the SARs ($28.97) and the vesting schedules, which provide insight into the company's and the compensation committee's expectations for future growth and profitability.

Key Highlights

1HCA Holdings, Inc. awarded stock appreciation rights (SARs) to named executive officers on February 8, 2012.
2Richard M. Bracken (CEO) received 900,000 SARs, and R. Milton Johnson (President & CFO) received 425,000 SARs.
3The SARs have a base price of $28.97 per share, reflecting the market price on the grant date.
4Half of the SARs are time-based, vesting over four years, while the other half are performance-based, tied to EBITDA targets for fiscal years 2012-2015.
5SARs are exercisable upon a change in control, subject to not being previously forfeited.
6Dr. Wayne J. Riley was granted 6,615 restricted stock units upon his election to the Board of Directors.
7All awards were made under the 2006 Stock Incentive Plan, as amended and restated.

HCA Healthcare, Inc. 8-K Report, Executive Changes (Feb 14, 2012)

Summary

Key Highlights

Frequently Asked Questions